证券代码：603259 证券简称：药明康德 公告编号：临 2025-052 无锡药明康德新药开发股份有限公司 1 年 6 月 25 日披露的《关于 2025 年第一次以集中竞价交易方式回购 A 股股份的 回购报告书》（公告编号：临 2025-042）。 二、回购股份的进展情况 截至 2025 年 7 月 28 日，公司在本次回购方案下累计通过集中竞价交易方 式回购 A 股股份 6,514,425 股，占公司总股本的 0.23%，回购最高价格为人民币 90.70 元/股，回购最低价格人民币 65.53 元/股，回购价格均价人民币 76.34 元/ 股，使用资金总额人民币 497,297,934.64 元（不含交易费用）。 关于调整回购股份价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 7 月 29 日召开第三届董事会第二十三次会议，审议通过了《关于调整回购股份价 格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购 ...

Market Overview - The Hang Seng Index closed at 25,524.45, down by 0.15%, while the Hang Seng China Enterprises Index fell by 0.34% to 9,145.92. The Hang Seng Tech Index decreased by 0.35% to 5,644.38, with intraday declines reaching 1.2% for the first two indices and a significant drop of 2% for the tech index [1] - Despite the index adjustments, southbound capital saw a substantial net purchase of Hong Kong stocks exceeding 10 billion HKD [1] Stock Performance - Notable gainers in the biopharmaceutical sector included WuXi AppTec (up 11.25%), with other companies like CSPC Pharmaceutical and Green Leaf Pharmaceutical also showing strong performance, rising over 8% [3] - The top-performing stocks included WuXi Biologics-B (up 33.33%), Chuangsheng Group-B (up 17.06%), and Dongyao Pharmaceutical-B (up 15.06%) [2] Sector Trends - Large tech stocks showed a narrowing of losses in the afternoon, with Alibaba slightly turning positive, while Tencent, JD.com, Meituan, and Kuaishou experienced declines within 1%. Xiaomi fell by 2.6%, and Baidu dropped nearly 2% [3] - The "anti-involution" sectors, including steel and photovoltaic stocks, saw a rebound, while sectors like banking, catering, and robotics generally declined [3]

人民财讯7月29日电，药明康德（603259）7月29日晚间公告，拟将2025年第一次以集中竞价交易方式回 购A股股份的回购股份价格上限由不超过90.72元/股（含）调整为不超过114.15元/股，本次回购方案的 其他内容不变。 ...

Market Overview - The Hong Kong stock market indices showed a recovery in the afternoon, with the Hang Seng Index and the Hang Seng China Enterprises Index down by 0.15% and 0.34% respectively, while the Hang Seng Tech Index fell by 0.35% after a larger drop of 2% during the day [1][2] - Despite the index adjustments, southbound funds significantly net bought over 10 billion HKD in Hong Kong stocks [1] Sector Performance - Large tech stocks saw a narrowing of losses in the afternoon, with Alibaba slightly turning positive, while Tencent, JD.com, Meituan, and Kuaishou experienced declines within 1%. Xiaomi continued to decline by 2.6% [2] - Biopharmaceutical stocks performed strongly, particularly in the innovative drug sector, with WuXi AppTec rising over 11%, and both CSPC Pharmaceutical and Luye Pharma increasing by over 8% [2] - The "anti-involution" sectors, including steel and photovoltaic stocks, showed a notable recovery, while oil, gambling, and semiconductor stocks mostly rose [2] - The three-child policy subsidy of 3600 yuan led to a mixed performance in related stocks, with some experiencing declines [2][6] Banking Sector - The banking sector faced declines, with several banks such as Chongqing Rural Commercial Bank and China Everbright Bank dropping over 3% [4][5] - Major banks like Industrial and Commercial Bank of China, China Construction Bank, and Agricultural Bank of China also saw declines [4] Biopharmaceutical Sector - WuXi AppTec reported a strong performance with a revenue of 20.8 billion yuan for the first half of 2025, a year-on-year increase of 20.64%, and a net profit surge of 101.92% [8] - The company expects continued double-digit growth in operating revenue, adjusting its growth forecast from 10-15% to 13-17% [8] Automotive Sector - Automotive dealership stocks rose against the trend, with Guanzhong Holdings increasing over 9% and Zhongsheng Holdings up over 6% [9][10] - UBS reported that the rebound in stock prices for Zhongsheng and Yongda Automotive is attributed to expectations of improved profit margins from new car sales due to government policies [10] Steel Sector - Steel stocks experienced gains, with Maanshan Iron & Steel rising over 8% and several other companies like Ansteel and Asia Pacific Resources also seeing increases [11][12] Apple-Related Stocks - Apple-related stocks were active, with AAC Technologies rising over 3% and other companies like GoerTek and BYD Electronics also showing gains [13] Future Outlook - Haitong Securities expressed optimism about the Hong Kong stock market, particularly in the technology sector, suggesting a focus on sectors with improving conditions and low valuations [15]

（文章来源：每日经济新闻） 每经AI快讯，7月29日，药明康德公告，将回购股份价格上限由不超过90.72元/股（含）调整为不超过 114.15元/股，回购方案其他内容不变。 ...

Core Viewpoint - The company reported strong financial performance for H1 2025, driven by high demand in the TEDIS business, leading to an upward revision of its annual performance guidance [1][4]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 20.8 billion yuan, a year-on-year increase of 20.6%, with continuous operations revenue growing by 24.2% [1]. - Adjusted net profit attributable to shareholders reached 6.31 billion yuan, up 44.4% year-on-year, while the net profit attributable to shareholders was approximately 8.56 billion yuan, reflecting a 101.9% increase [1]. - For Q2 2025, the company reported revenue of 11.14 billion yuan, a 20.4% year-on-year growth, and adjusted net profit of 3.64 billion yuan, up 47.9% [1]. Group 2: Business Segments - **Chemical Business (WuXi Chemistry)**: H1 2025 revenue was 16.3 billion yuan, a 33.5% increase, with an adjusted gross margin of 49.0%, up 5.2 percentage points. The TIDES business saw revenue of 5.03 billion yuan, a significant 141.6% increase [2]. - **Testing Business (WuXi Testing)**: H1 2025 revenue was 2.69 billion yuan, a slight decline of 1.2%, with an adjusted gross margin of 25.1%, down 12.3 percentage points. Q2 2025 showed signs of recovery with a 5.5% year-on-year growth in laboratory analysis and testing services [3]. - **Biology Business (WuXi Biology)**: H1 2025 revenue was 1.25 billion yuan, a 7.1% increase, with an adjusted gross margin of 36.4%, down 0.7 percentage points. The business contributed to over 30% of new customer acquisition [4]. Group 3: Market Dynamics - The company has a strong international presence, with approximately 85% of revenue coming from overseas clients. Revenue from U.S. clients was 14.03 billion yuan, up 38.4%, while revenue from Chinese clients decreased by 5.2% to 3.15 billion yuan [5]. - The company’s order backlog for continuous operations reached 56.69 billion yuan, a 37.2% year-on-year increase, indicating robust future growth potential [4]. Group 4: Future Outlook - The company has revised its 2025 revenue growth target for continuous operations from 10-15% to 13-17%, with overall revenue targets adjusted from 41.5-43 billion yuan to 42.5-43.5 billion yuan [4]. - The company expects to maintain strong growth trends in the second half of 2025, supported by high demand in the TEDIS business [4].

Core Insights - Morgan Stanley's research report indicates that WuXi AppTec's revenue and adjusted net profit for the first half of the year increased by 21% and 44% year-on-year, exceeding the bank's expectations by 5% and 15% respectively, with the second quarter showing increases of 20% and 48% [1] - The management has raised the full-year revenue growth guidance to 13% to 17%, suggesting revenue will be between 42.5 billion to 43.5 billion yuan, reflecting confidence in the second half performance and providing a buffer against last year's high base [1] - The TIDES business is expected to be a key driver for the full-year performance, with its revenue in the first half increasing 1.42 times to 5 billion yuan, accounting for over 30% of the chemical business's total revenue and approximately 24% of the company's overall revenue; solid-phase peptide synthesis capacity is anticipated to double by 2025 [1] - Morgan Stanley has set a target price of 92 yuan for WuXi AppTec's A-shares and maintains an "Overweight" rating [1] Related Events - Major banks have issued ratings for WuXi AppTec, with Morgan Stanley stating that the company's first-half performance exceeded expectations and maintaining a target price of 92 yuan and an "Overweight" rating [2] - Bank of America has raised its target price for WuXi AppTec to 115.7 Hong Kong dollars, citing strong growth in new orders during the first half [2]

大行评级｜大摩：药明康德上半年业绩超预期 予A股目标价92元及"增持"评级 大行评级｜美银：上调 药明康德目标价至115.7港元 上半年新增订单增长强劲 相关事件 花旗发表研究报告指，药明康德(2359.HK)上半年收入按年增长21%至208亿元人民币，期内净利润增长 102%至86亿元人民币，若撇除一次性收益增幅为26%，符合此前盈喜公告。管理层已将全年收入指引 由原预期的415亿至430亿元人民币，上调至介乎425亿至435亿元人民币，预料持续经营业务增长13%至 17%，原预期增长10%至15%，并有信心进一步提升经调整净利率。花旗基于估值给予药明康德目标价 95港元，评级为买入，将在业绩电话会议后再作更新。 ...

港股收盘，恒指收跌0.15%，科指收跌0.35%。药明康德(02359.HK)收涨11.25%。 ...

恒生指数收盘跌0.15%，恒生科技指数跌0.35%。医药股涨幅居前，药明康德涨约11%，科济药业涨约 7%，君圣泰医药-B涨约6%。 ...